Tenpoint Therapeutics secured FDA approval for Yuvezzi, a dual‑agent eye drop (carbachol and brimonidine) for adult presbyopia, becoming the first dual‑mechanism topical treatment cleared in the U.S. The approval comes alongside financing commitments totaling up to $235 million, including equity and debt facilities to support commercialization. Tenpoint said the financing package comprises $85 million in Series B proceeds and a $150 million non‑dilutive senior secured term loan, aimed at product launch and marketing. The company claims the dual‑agent approach differentiates Yuvezzi from single‑mechanism competitors and may offer an alternative to reading glasses and contact lenses. The approval validates an eye‑drop pathway for presbyopia and sets a financing precedent for small biotechs moving into commercialization. Market uptake will depend on payer coverage, physician adoption, and the comparative clinical profile versus incumbent topical therapies.